Overview

This trial is active, not recruiting.

Condition cystic fibrosis lung disease
Treatments 6% hypertonic saline (hs), 4ml, 0.9% isotonic saline (is), 4ml
Phase phase 2
Sponsor Heidelberg University
Collaborator German Center for Lung Research
Start date June 2012
End date November 2016
Trial size 40 participants
Trial identifier NCT01619657, UKH-PIHSNC-1

Summary

The purpose of this study is to assess whether 6% hypertonic saline (HS) is a safe and effective preventive therapy in newborns and infants with cystic fibrosis (CF).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose prevention
Arm
(Experimental)
Inhalation with 6% Hypertonic Saline twice daily over 1 year
6% hypertonic saline (hs), 4ml MucoClear® 6%
Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
(Active Comparator)
Inhalation with 0.9% Isotonic Saline twice daily over 1 year
0.9% isotonic saline (is), 4ml Normal Saline
Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.

Primary Outcomes

Measure
Number of patients in both treatment groups with adverse events (AEs) and serious adverse events (SAEs)
time frame: during the 52 week treatment period

Secondary Outcomes

Measure
Rate of protocol-defined pulmonary exacerbations
time frame: during the 52 week treatment period
Time to first pulmonary exacerbation in both treatment groups
time frame: during the 52 week treatment period
Proportion of children with morphological and/or functional changes due to CF lung disease at baseline and after 1 year of inhalation
time frame: during the 52 week treatment period
Extent and severity of bronchial dilatation
time frame: during the 52 week treatment period
Proportion of children with impairments in lung function
time frame: during the 52 week treatment period
Severity of impairment in lung function test
time frame: during the 52 week treatment period
Health-related quality of life
time frame: during the 52 week treatment period
Change in anthropometric and basic respiratory parameters
time frame: during the 52 week treatment period
Proportion of patients with new isolation of CF pathogen
time frame: during the 52 week treatment period
Time to first isolation of a CF pathogen
time frame: during the 52 week treatment period

Eligibility Criteria

Male or female participants up to 4 months old.

Inclusion Criteria: 1. Confirmed diagnosis of CF established in neonatal period either via CF newborn screening (NBS) or because of symptoms typical for CF (e.g. meconium ileus), positive family history or positive prenatal screening and fulfilling at least one of the following three criteria: - sweat chloride ≥ 60mEq/L - two CF causing mutations of CFTR gen - alterations of transepithelial potential difference of nasal or rectal epithelia typical for CF. 2. Age at enrolment is 0 to 4 months. 3. Patient's and parent's ability to comply with medication use, study visits, and study procedures is judged by the investigator (therefore parents have to understand the character of the study and individual consequences). 4. Participation in this study is voluntary. Only patients, whose parents or legal guardians gave written consent, are included. Exclusion Criteria: 1. Born < 30 weeks gestation. 2. Prolonged mechanical ventilation in the first 3 months of life. 3. A significant medical disease or condition other than CF likely to interfere with the child's ability to complete the entire protocol. 4. Previous major surgery except for meconium ileus. 5. Other major organ dysfunction, excluding pancreatic or hepatic dysfunction or another condition due to cystic fibrosis. 6. Physical findings that would compromise the safety of the subject or the quality of the study data as determined by investigator. 7. History of adverse reaction to sedation. 8. Known hypersensitivity to study treatment. 9. Participation in other interventional studies at the same time. Criteria, which lead to a displacement of the procedures in sedation until the child has recovered: - Clinically significant upper airway obstruction as determined by investigator (e.g. severe laryngomalacia, markedly enlarged tonsils, significant snoring, diagnosed obstructive sleep apnoea). - Acute intercurrent respiratory infection, defined as an increase in cough, wheezing, or respiratory rate with onset in 2 weeks preceding visit. - Oxygen saturation <95% before initial pulmonary function test or initial MRI. - Severe gastroesophageal reflux, defined as persistent frequent emesis despite anti-reflux therapy.

Additional Information

Official title Randomized, Double-blind, Controlled Pilot Study on Safety of Hypertonic Saline as Preventive Inhalation Therapy in Newborns and Infants With Cystic Fibrosis
Principal investigator Marcus A Mall, MD
Description Cystic fibrosis (CF) remains one of the most common lethal genetic diseases in Europe and North America. Despite a substantial increase in life expectancy over the past decades, many CF patients still die during young adulthood due to chronic progressive CF lung disease that is caused by defective fluid transport by airway epithelia causing dehydration of airway surfaces, which in turn leads to impaired mucociliary clearance, chronic airway mucus obstruction, inflammation and infection. Recent evidence from studies in a mouse model of CF lung disease suggest that preventive improvement of airway surface hydration may be an effective treatment of early and reversible mucus obstruction and inflammation, and thus delay or ameliorate progressive damage in lungs of CF patients. Hypertonic saline (HS) is an osmotic agent that improves airway surface hydration, and inhalation of 6% HS is already an established, safe, and effective maintenance therapy that improves mucociliary clearance and lung function, and reduces pulmonary exacerbations in older children (> 6 years) and adults with chronic CF lung disease and fixed lung damage. However, the effect of HS as a preventive therapy has not been studied, and no other therapies are available for preventive improvement of airway dehydration and mucociliary dysfunction in CF. This investigator initiated clinical trial is a monocentric, randomized, double-blind, controlled pilot study on safety and efficacy of a preventive and early inhalation with HS in newborns and infants with CF who are diagnosed in the newborn period either by CF newborn screening (CF-NBS) or for another reason (e.g. meconium ileus) and are younger than 4 months of age at the time of enrolment. Participating patients will be randomized to 6% HS or 0.9% isotonic saline (IS) as active comparator. In both groups, patients will inhale their study solution twice daily over 52 weeks. At the beginning, during and at the end of the study, different measurements will be undertaken to determine effects of HS on safety, radiologic and/or functional alterations of the lung, number of exacerbations, time to first detection of a CF pathogen, and health-related quality of life. We expect that the results of this study will provide first evidence on the safety and efficacy of a preventive therapy that improves airway surface hydration and targets a CF basic defect and may thus delay and/or ameliorate chronic damage of the lungs of patients with CF.
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by Heidelberg University.